Charming Medical Ltd (MCTA)
Operating through its subsidiaries and under the Beauty Lab brand in Hong Kong, Charming Medical Limited delivers a comprehensive suite of beauty, wellness, and postpartum services. These services encompass womb-warming therapy, BTS (Beauty, Tailor-made, Slim) pelvic detox, agarwood moxibustion, TCM-inspired prenatal massages, and Indonesian traditional abdominal binding. In addition to these treatments, the company manufactures and distributes various products. Their product line features TCM-inspired supplements, including the Beauty Lab home herbal uterine care patch, probiotic intimate wash, and Yin nourishing pill sets. They also offer beauty products like a ginseng soothing anti-allergy moisturizing wash for various skin issues and solutions for scalp health. The company further provides consultancy services, offering technical training in TCM-inspired therapies and dietary guidance to other well-regarded beauty salons, massage centers, and similar institutions. These services and products are specifically formulated to alleviate premenstrual syndrome, menstrual irregularities, dysmenorrhea, leukorrhea, pelvic inflammatory disease, menopausal symptoms, and concerns related to breast and uterine health. They also contribute to enhancing overall physical strength and balancing endocrine functions, addressing a wide array of common women's health challenges. Charming Medical operates its own network of wellness centers. Founded in 2016, the company maintains its headquarters in Causeway Bay, Hong Kong.
Sector: Services-Misc Health & Allied Services, NEC
Industry: Medical - Care Facilities
Charming Medical Limited Class A Ordinary Shares
No splits on record
Nothing in MCTA's public trading history: no forward or reverse split has affected the share count.
| Period | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Currency | USD | USD | USD |
| Period Ending | 2025-03-31 | 2024-03-31 | 2023-03-31 |
| Revenue | $6.22M | $6.02M | $3.53M |
| YoY Growth | 3.4% | 70.4% | - |
| Cost of Revenue | $2.04M | $2.1M | $2.04M |
| Gross Profit | $4.18M | $3.91M | $1.49M |
| Gross Margin | 67.2% | 65.1% | 42.3% |
| Research and Development | $0 | $0 | $0 |
| Selling, General, and Administrative | $2.32M | $2.35M | $1.66M |
| Other | $474K | $555K | $353K |
| Total Operating Expenses | $2.79M | $2.91M | $2.02M |
| Operating Income (EBIT) | $1.39M | $1.01M | -$521K |
| Operating Margin | 22.3% | 16.8% | -14.8% |
| Interest Expense | $21K | $26K | $20K |
| Interest Income | $64K | $20K | $10K |
| Other Income (Expense) | $46K | -$5K | $101K |
| Income Before Tax (EBT) | $1.44M | $1M | -$420K |
| Income Tax Expense | $236K | $182K | -$85K |
| Net Income | $1.2M | $778K | -$305K |
| Net Income Margin | 19.3% | 12.9% | -8.6% |
| Supplementary Data | |||
| EPS | 0.07 | 0.05 | -0.02 |
| Diluted EPS | 0.07 | 0.05 | -0.02 |
| Weighted Average OS | 16.94M | 16.94M | 16.94M |
| EBITDA | $1.72M | $1.42M | -$189K |
| EBITDA Margin | 27.6% | 23.6% | -5.4% |
| Period | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Currency | USD | USD | USD |
| Period Ending | 2025-03-31 | 2024-03-31 | 2023-03-31 |
| Assets | |||
| Current Assets | |||
| Cash and Cash Equivalents | $817K | $2.1M | $1.93M |
| Short-Term Investments | $1.94M | $0 | $0 |
| Cash and Short-Term Investments | $2.76M | $2.1M | $1.93M |
| Accounts Receivable | $579K | $1.54M | $2.12M |
| Inventory | $27K | $28K | $66K |
| Other Current Assets | $0 | $0 | $0 |
| Total Current Assets | $3.37M | $3.67M | $4.12M |
| Long-Term Assets | |||
| Property, Plant & Equipment Net | $1.21M | $922K | $1.8M |
| Goodwill | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 |
| Deferred Tax Assets | $77K | $211K | $273K |
| Other Long-Term Assets | $701K | $81K | $194K |
| Total Long-Term Assets | $1.99M | $1.21M | $2.26M |
| Other Assets | $0 | $0 | $0 |
| Total Assets | $5.36M | $4.88M | $6.38M |
| Liabilities | |||
| Current Liabilities | |||
| Accounts Payable | $3K | $0 | $2K |
| Short-Term Debt | $314K | $443K | $590K |
| Current Income Tax Payable | $221K | $119K | $0 |
| Current Unearned Revenue | $3.46M | $4.5M | $5.6M |
| Other Current Liabilities | $0 | $0 | $0 |
| Total Current Liabilities | $4.95M | $5.88M | $7.17M |
| Long-Term Liabilities | |||
| Long-Term Debt | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 |
| Total Long-Term Liabilities | $358K | $148K | $484K |
| Other Liabilities | $0 | $0 | $0 |
| Total Liabilities | $5.31M | $6.03M | $7.65M |
| Stockholders' Equity | |||
| Preferred Stock | $0 | $0 | $0 |
| Common Stock | $2K | $2K | $2K |
| Retained Earnings | $119K | -$1.08M | -$1.16M |
| Comprehensive Income & Other | -$4K | $205 | $4K |
| Other Stockholders' Equity | -$72K | -$1K | $2K |
| Total Equity | $49K | -$1.08M | -$1.16M |
| Minority Interest | $0 | -$67K | -$110K |
| Total Liabilities and Equity | $5.36M | $4.95M | $6.49M |
| Supplementary Data | |||
| Total Debt | $1.16M | $961K | $1.81M |
| Net Debt | $344K | -$1.14M | -$120K |
| Period | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Currency | USD | USD | USD |
| Period Ending | 2025-03-31 | 2024-03-31 | 2023-03-31 |
| Operating Activities | |||
| Net Income | $1.2M | $822K | -$336K |
| Depreciation & Amortization | $263K | $392K | $211K |
| Deferred Income Tax | $135K | $62K | $0 |
| Stock-Based Compensation | $0 | $0 | $0 |
| Changes in Working Capital: | |||
| Accounts Receivable | -$44K | -$165K | -$154K |
| Inventory | $1K | $38K | -$56K |
| Accounts Payable | -$205K | $210K | $180K |
| Other Working Capital | -$913K | -$1.03M | $2.53M |
| Total Working Capital Change | -$1.16M | -$943K | $2.5M |
| Other Non-Cash Items | -$11K | -$37K | $61K |
| Net Cash from Operating | $426K | $295K | $2.43M |
| Investing Activities | |||
| Capital Expenditures | -$288K | -$211K | -$606K |
| Acquisitions | $0 | $0 | $0 |
| Purchases of Investments | -$1.94M | $0 | $0 |
| Sales of Investments | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 |
| Net Cash from Investing | -$2.23M | -$211K | -$606K |
| Financing Activities | |||
| Debt Repaid | -$180K | -$33K | - |
| Common Stock Issuance | $0 | $0 | $0 |
| Common Stock Repurchases | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 |
| Other Financing Activities | $472K | $216K | -$1.25M |
| Net Cash from Financing | $521K | $100K | -$1.43M |
| Forex Effect | -$5K | -$11K | $6K |
| Net Change in Cash | -$1.29M | $174K | $403K |
| Supplementary Data | |||
| Operating Cash Flow | $426K | $295K | $2.43M |
| Capital Expenditure | -$288K | -$211K | -$606K |
| Free Cash Flow | $138K | $85K | $1.83M |
| Cash at Beginning | $2.1M | $1.93M | $1.53M |
| Cash at End | $817K | $2.1M | $1.93M |